Assembly Biosciences, Inc. (ASMB) Stock Price & Analysis
Assembly Biosciences, Inc. (ASMB) is trading at USD 22.36, down 0.62% today, as of November 18, 2026 at 20:43 UTC (US market open; quotes may be delayed), according to Nexqual market data.
ASMB last closed at USD 22.36; today's session has ranged USD 22.07–23.5 on volume of 342,644 shares. Market capitalization is —, with a 52-week range of USD 19.2–39.71 (NMS). Source: Nexqual, retrieved November 18, 2026 at 20:43 UTC.
What changed for ASMB since Aug 31, 2025
The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).
- Assembly Biosciences, Inc. (ASMB) stock went from USD 24.7 (close of the week of Aug 25, 2025, split-adjusted) to USD 22.36, a -9.5% price change; the S&P 500 (SPY) moved +14.9% over the same period.
- ASMB revenue over the last four reported quarters (through Sep 30, 2026) was $67.0M, +135.0% vs $28.5M in fiscal year 2024 (ended Dec 31, 2024), the last full year filed before September 2025; net income -$40.2M → -$11.1M (SEC 10-K / 10-Q).
- Analyst actions on ASMB in the last 120 days: 4 (0 upgrades or target raises, 2 downgrades or target cuts); most recent UBS, Nov 3, 2026.
Also available as compact Markdown for AI agents: nexqual.com/ASMB.md
Key facts (ASMB)
- Last four reported quarters (through Sep 30, 2026): revenue $67.0M, net income -$11.1M (-16.6% margin), free cash flow -$40.7M (SEC filings).
- Insider open-market sales, last ~7 months: 5 Form 4 filings, $238K; 5 not under a Rule 10b5-1 plan ($238K); 3 by opportunistic insiders (3 outside 10b5-1 plans), 1 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Total return with dividends: 1Y -37.7% vs S&P 500 +11.9%; 5Y -19.0% vs S&P 500 +66.7%.
- Dividend: ASMB paid no cash dividend in the last five years.
- Short interest: 19.82% of float (as of 2026-10-30), 13.6 days to cover.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ASMB)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $6.3M | $0K | $7.2M | $28.5M | $72.3M | $67.0M |
| Operating income | -$133M | -$94.1M | -$64.6M | -$45.4M | -$12.1M | -$21.3M |
| Net income | -$130M | -$93.1M | -$61.2M | -$40.2M | -$6.1M | -$11.1M |
| EPS (diluted) | -$36.00 | -$23.08 | -$13.38 | -$6.69 | -$0.55 | — |
| Free cash flow | -$96.5M | -$84.6M | $22.5M | -$51.1M | -$41.2M | -$40.7M |
| Operating margin | -2121.7% | — | -902.5% | -159.3% | -16.8% | -31.8% |
| Net margin | -2076.4% | — | -854.8% | -140.9% | -8.5% | -16.6% |
| Revenue growth | -92.1% | -100.0% | — | +298.2% | +153.5% | — |
| Cash + short-term investments | $147M | $91.6M | $130M | $112M | $248M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Sep 30, 2026) (ASMB)
Insider sales (SEC Form 4, open-market, last ~7 months) (ASMB)
0 of 5 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-11-02 | Bjorkquist Jeanette M | PFO and PAO | 727 | $14K | 4% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-11-02 | White Nicole S | Chief Manufacturing Officer | 2,593 | $51K | 4.2% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-11-02 | Gaggar Anuj | Chief Medical Officer | 2,593 | $51K | 4.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-11-02 | Okazaki Jason A | CEO and President | 6,202 | $122K | 3.1% | No | Routine (sold in Mar each year 2023–2025; this trade is outside those months) |
| 2026-06-17 | Bjorkquist Jeanette M | PFO and PAO | 29 | $1K | 0.2% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (ASMB)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-11-03 | UBS | Target lowered | Buy | $52 → $48 |
| 2026-09-01 | Mizuho | Target lowered | Outperform | $53 → $45 |
| 2026-09-01 | UBS | Initiated | Buy | $52 |
| 2026-08-18 | HC Wainwright & Co. | Reiterated | Buy | $50 |
Total return (dividends reinvested) (ASMB)
| 1Y (from 2025-11-18) | 5Y (from 2021-11-15) | |
|---|---|---|
| Total return | -37.7% | -19.0% |
| S&P 500 (SPY) | +11.9% | +66.7% |
| Per year | -37.7% | -4.1% |
| Volatility (annualized) | 60.1% | 58.9% |
| Max drawdown | -49.3% (Nov 2025→Nov 2026) | -69.8% (Nov 2021→Oct 2023) |
Dividends (ASMB)
ASMB paid no cash dividend in the last five years.
Short interest (ASMB)
3,032,675 shares sold short, 19.82% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 2,822,392 shares (+7.5%). Days to cover: 13.6 (short shares ÷ average daily volume).
ASMB earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Sep 30, 2026 | −$0.93 | −$0.49 | Miss −89.8% | — |
| — | Quarter ended Jun 30, 2026 | −$0.20 | −$0.67 | Beat +70.1% | — |
| — | Quarter ended Mar 31, 2026 | −$0.54 | −$0.64 | Beat +15.6% | — |
| — | Quarter ended Dec 31, 2025 | $2.48 | −$0.85 | Beat +$3.33 | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
ASMB recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Nov 16, 2026 | Schedule 13G/A | JANUS HENDERSON GROUP Ltd.: 3.3% of shares, passive 5%+ holder (amended) |
| Nov 12, 2026 | 10-Q | Quarterly report · period ended Sep 30, 2026 |
| Nov 12, 2026 | 8-K | Quarterly results |
| Aug 14, 2026 | Schedule 13G/A | Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC: 7.8% of shares, passive 5%+ holder (amended) |
| Aug 14, 2026 | 8-K/A | Quarterly results |
| Aug 13, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 13, 2026 | 8-K | Completed an acquisition or sale of assets |
| Aug 13, 2026 | Schedule 13G/A | JANUS HENDERSON GROUP Ltd.: 6.9% of shares, passive 5%+ holder (amended) |
| Aug 4, 2026 | Schedule 13G/A | Farallon Capital Management, L.L.C., Farallon Capital Partners, L.P.: 8.1% of shares, passive 5%+ holder (amended) |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
ASMB suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | GILEAD SCIENCES, INC. (GILD) | “our ability to realize the potential benefits of our collaboration with Gilead Sciences, Inc. (Gilead), including all financial aspects of the collaboration and equity investments;” |
| Partner | Arbutus Biopharma Corp (ABUS) | “Reflects net amounts refundable to us after final reconciliation of costs for the clinical trial conducted pursuant to the Clinical Trial Collaboration Agreement with Arbutus Biopharma Corporation, which was terminated in February 2023.” |
Quoted from the company's 10-K filed Mar 19, 2026.
ASMB company outlook (results filed Nov 12, 2026)
- “Profit-Share option for the HSV helicase primase inhibitor program – – Received first $75 million collaboration extension fee from Gilead; cash runway projected into 2029 – SOUTH SAN FRANCISCO, Calif. – November 12, 2026 – Assembly Biosciences, Inc.”
Quoted word-for-word from the SEC 8-K results press release.
ASMB analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $1.29 | $1.37 | -5.8% | $42.8M | 3 |
| Next quarter (ends Mar 2027) | $-0.25 | $0.02 | −$0.27 | $10.6M | 1 |
| Current fiscal year (ends Dec 2026) | $-0.55 | $0.42 | −$0.97 | $56.6M | 2 |
| Next fiscal year (ends Dec 2027) | $-2.72 | $-1.89 | −$0.83 | $33.3M | 4 |
Key Statistics (as of November 18, 2026 at 20:43 UTC)
| Price | USD 22.36 |
|---|---|
| Change | ▼ 0.62% (down) |
| Previous Close | USD 22.36 |
| Open | USD 22.36 |
| Day Range | USD 22.07 – 23.5 |
| 52-Week Range | USD 19.2 – 39.71 |
| Volume | 342,644 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (ASMB)
Nexqual's technical model rates ASMB "NEUTRAL" based on 2 bullish and 3 bearish signals across 129 daily candles, as of November 18, 2026 at 20:43 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 55.88 (neutral) |
| vs SMA50 | Below (USD 22.48) |
| MACD | -0.16 (negative) |
Earnings (ASMB)
| EPS Estimate | USD 1.29 |
|---|---|
| Revenue Estimate | $42.84M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD -0.93 vs est -0.49 ▼ miss |
| 2026-06-30 | USD -0.2 vs est -0.67 ▲ beat |
| 2026-03-31 | USD -0.54 vs est -0.64 ▲ beat |
| 2025-12-31 | USD 2.48 vs est -0.85 ▲ beat |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
Financials & Fundamentals (ASMB)
| Total Revenue | $67.01M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -72.60% |
| Gross Margin | -0.43% |
| Operating Margin | -31.83% |
| Profit Margin | -16.57% |
| ROE | -4.61% |
| Debt / Equity | 0.01 |
| Current Ratio | 12.89 |
| Total Cash | $314.26M |
| Total Debt | $2.21M |
| Free Cash Flow (last four quarters to Sep 2026, SEC 10-Q / 10-K) | -$40.68M (-60.7% of revenue) |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
Financial Health Score (ASMB)
Nexqual rates Assembly Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of November 18, 2026 at 20:43 UTC.
| Growth | Strong — Revenue +80% (last 4 quarters to Sep 2026 vs the 4 before, SEC) |
|---|---|
| Profitability | Critical — Gross margin -0%, operating -32% (last 12 months) |
| Balance Sheet | Strong — $314M cash vs $2M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$41M (last 4 quarters to Sep 2026, SEC), burning cash |
| Efficiency | Critical — ROE -4%, ROA -3.4% (last 4 quarters, SEC) |
Ownership (ASMB)
| Insider Ownership | +27.83% |
|---|---|
| Institutional Ownership | +70.78% |
| Shares Outstanding | 20.48M |
| Float | 10.28M |
| Short % of Float | +19.82% |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
From Assembly Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Partnerships
- The $10.0 million payment received in connection with the First Amendment to the Gilead Collaboration Agreement is creditable towards future collaboration-related payments payable by Gilead.
- If Gilead exercises its opt-in right to any current or future program under the collaboration, we are eligible to receive up to $330.0 million in potential regulatory and commercial milestones on that program, in addition to royalties ranging from the high single-digits to high teens, depending on the clinical stage of the program at the time of the opt-in.
Legal & Regulatory Risks (Item 1A, quoted)
- We are and will be subject to extensive and costly government regulation, and the failure to comply with these regulations may have a material adverse effect on our operations and business.
- We face the risk of product liability claims and might not be able to obtain insurance.
- We might be exposed to liability claims associated with the use of hazardous materials and chemicals.
- Our research, development and manufacturing activities and/or those of our third-party contractors might involve the controlled use of hazardous materials and chemicals.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KOD | Kodiak Sciences Inc | USD 98.14 | ▲ 1.38% |
| BLTE | Belite Bio, Inc | USD 157.14 | ▼ 0.37% |
| ORKA | Oruka Therapeutics, Inc. | USD 95.92 | ▼ 0.42% |
| IMVT | Immunovant, Inc. | USD 33.3 | ▲ 0.27% |
| AXSM | Axsome Therapeutics, Inc. | USD 133.9 | ▼ 1.51% |
| IBRX | ImmunityBio, Inc. | USD 6.71 | ▲ 7.19% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:43 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt